Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GEN1056 in advanced solid tumors
NCT05586321Phase 1Completed
- Sponsor
- Genmab
- Start
- Oct 2022
- Primary completion
- Oct 2025
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 3
01
Overview
Phase 1, open-label, single-arm trial of GEN1056 in solid tumor, sponsored by Genmab. Primary endpoints: Dose Limiting Toxicity at 21 days, Adverse Events and 1 more. Started Oct 2022; status: completed.
02
Drugs
GEN1056
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05586321.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05586321.